Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial

Key Findings

• ●Anakinra significantly reduced attack frequency (1.7 vs 3.5/month, P=0.037)
• ●6 anakinra patients vs 0 placebo had <1 attack/month (P=0.005)
• ●First RCT of anakinra in colchicine-resistant FMF

Referenced in (1 disease)